Zafgen, Inc. (NASDAQ:ZFGN) has been assigned a consensus rating of “Hold” from the five analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $6.38.

A number of equities analysts recently issued reports on the company. Zacks Investment Research upgraded Zafgen from a “hold” rating to a “buy” rating and set a $3.75 price objective for the company in a report on Saturday. ValuEngine upgraded Zafgen from a “strong sell” rating to a “sell” rating in a report on Thursday, July 6th. Finally, Roth Capital assumed coverage on Zafgen in a report on Thursday, April 20th. They set a “buy” rating and a $9.00 price objective for the company.

Zafgen (NASDAQ:ZFGN) traded up 2.10% during mid-day trading on Friday, hitting $3.40. The stock had a trading volume of 79,526 shares. The stock’s 50-day moving average price is $3.50 and its 200-day moving average price is $4.08. The stock’s market cap is $93.06 million. Zafgen has a 12 month low of $2.89 and a 12 month high of $5.46.

Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.52) by $0.03. During the same period in the previous year, the firm posted ($0.55) EPS. On average, analysts predict that Zafgen will post ($2.23) earnings per share for the current year.

In other Zafgen news, insider Dennis D. Kim acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 11th. The stock was bought at an average price of $3.39 per share, for a total transaction of $33,900.00. Following the acquisition, the insider now directly owns 21,443 shares in the company, valued at $72,691.77. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 21.20% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the stock. OxFORD Asset Management LLP acquired a new position in Zafgen during the second quarter worth about $364,000. Dimensional Fund Advisors LP boosted its position in Zafgen by 31.8% in the second quarter. Dimensional Fund Advisors LP now owns 584,159 shares of the biopharmaceutical company’s stock worth $2,050,000 after buying an additional 140,848 shares during the last quarter. Vanguard Group Inc. boosted its position in Zafgen by 15.7% in the second quarter. Vanguard Group Inc. now owns 883,838 shares of the biopharmaceutical company’s stock worth $3,102,000 after buying an additional 119,902 shares during the last quarter. GSA Capital Partners LLP acquired a new position in Zafgen during the second quarter worth about $259,000. Finally, LMR Partners LLP acquired a new position in Zafgen during the second quarter worth about $299,000. Institutional investors own 52.54% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Zafgen, Inc. (ZFGN) Receives Average Rating of “Hold” from Brokerages” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/12/zafgen-inc-zfgn-receives-average-rating-of-hold-from-brokerages.html.

Zafgen Company Profile

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.